Shanghai Fudan Forward S&T Co., Ltd (600624.SS), also known as Shanghai Fudan Fuhua Technology Co., Ltd, engages primarily in the research, development, production, and sale of pharmaceuticals alongside software development and high-tech park operations. The company operates three core business segments: biomedicine, featuring chemical drugs, Chinese patent medicines, freeze-dried powder injections, and solid preparations including digestive system drugs such as injectable glutathione and isosorbide nitrate tablets; nervous system drugs such as carbamazepine tablets and neuroleptic tablets; antineoplastic drugs such as flutamine tablets and tamoxifen citrate tablets; circulatory system drugs such as shuangyipine and triptolioid tablets; and immune regulation drugs; digital economy, centered on financial insurance system software products exported to Japan through subsidiary Shanghai Zhonghe Software Co., Ltd; and high-tech parks, encompassing self-owned housing leasing, real estate development, investment promotion, consulting, and property management services. Founded in 1984 as Fudan University Science and Technology Development Company and listed on the Shanghai Stock Exchange in 1993, the company is headquartered in Shanghai, China, with primary operations in the domestic market and software exports to Japan; it employs over 1,400 people across 28 subsidiaries. Recent developments include a major share transfer in November 2025, whereby controlling shareholder Fudan University transferred shares to Fuxin Fangao and Guosheng Investment under a Share Transfer Framework Agreement, prompting stock price fluctuations and potential ownership changes; additionally, the company reported improved half-year net profits in 2025 driven by subsidiaries Shanghai Zhonghe Software and Shanghai Fuhua High-Tech Park Development, alongside completion of industrial and commercial registrations for wholly-owned subsidiaries and board resolutions on strategic matters.